Table 4.
Survival of HRA devices and the reference THA group. Endpoint was defined as revision of any component for any reason. Survival rates according to Kaplan-Meier analysis
| n | Follow-up, years | At risk, | 5-year survival | At risk, | 8-year survival | At risk, | 10-year survival | |
|---|---|---|---|---|---|---|---|---|
| mean (range) | 5 years | (95% CI) | 8 years | (95% CI) | 10 years | (95% CI) | ||
| BHR | 2,141 | 7.6 (0.0–12.7) | 1,703 | 96 (95–97) | 1,146 | 93 (92–94) | 698 | 91 (89–92) |
| ASR | 1,051 | 6.5 (0.0–9.8) | 864 | 88 (86–90) | 253 | 72 (69–76) | 0 | – |
| ReCap | 846 | 5.5 (0.0–9.7) | 546 | 94 (93–96) | 183 | 91 (89–94) | 0 | – |
| Conserve Plus | 579 | 5.3 (0.0–8.7) | 428 | 95 (93–97) | 6 | – | 0 | – |
| Durom | 350 | 6.9 (0.0–9.1) | 326 | 95 (93–98) | 103 | 92 (89–96) | 0 | – |
| Corin (Cormet) | 101 | 9.1 (0.7–11.6) | 95 | 94 (89–99) | 72 | 92 (87–97) | 46 | 86 (78–94) |
| All HRAs | 5,086 | 6.8 (0.0–12.7) | 3,848 | 94 (93–94) | 1,724 | 88 (87–89) | 701 | 86 (84–87) |
| Reference THAs | 6,485 | 7.9 (0.0–13.0) | 4,801 | 94 (94–95) | 3,711 | 93 (92–94) | 2,402 | 92 (91–92) |